Therapeutic options for patients with Hodgkin's disease and non-Hodgkin's lymphoma who relapse after autologous transplant

Curr Treat Options Oncol. 2005 Jul;6(4):279-87. doi: 10.1007/s11864-005-0032-z.


Although autologous stem cell transplantation for Hodgkin's disease and non-Hodgkin's lymphoma has become a safe and effective therapy, relapses after transplant are common. Emerging data indicate that an increasing number of patients can be re-induced into durable complete remission. Conventional dose- salvage chemotherapy and single-agent monoclonal antibody treatment provided limited success, but combination chemotherapy-monoclonal antibody treatments, second autografts, and reduced-intensity conditioning allografts provide encouraging results. For some patients, the best strategy may consist of participation in phase I to II studies of novel agents. New strategies designed to prevent relapse after autograft include cytokine therapy such as interleukin-2 in combination with monoclonal antibodies and the use of autologous antilymphoma vaccines.

Publication types

  • Review

MeSH terms

  • Clinical Trials as Topic
  • Combined Modality Therapy
  • Hodgkin Disease / therapy*
  • Humans
  • Lymphoma, Non-Hodgkin / therapy*
  • Neoplasm Recurrence, Local / prevention & control
  • Neoplasm Recurrence, Local / therapy*
  • Remission Induction / methods
  • Stem Cell Transplantation*